The special issue “Current topics in Pharmacogenomics”, will be wonderful reference for new generation pharmacists &
future pharmacists to understand the current status of Pharmacogenomics (Future medicine or personalized medicine) and its
“No two individuals are alike” and diversities among the individuals can potentially contribute their reaction (positive or
negative) to the drug. The main focus of Human Genome Project is developing personalized medicine based on the genome
content of the individual to maximize the drug efficacy and minimize the un-wanted side effects. Disciplines such as Biotechnology,
Bioinformatics, Genomics, Genetic Engineering, Molecular Biology, Pharmaceuticals Sciences, Clinical Practice, and
Mathematics are the core of Pharmacogenomics. The main focus of this issue is to bring novel research topics, development of
new pharmacogenomics tools in personalized medicine for major diseases and few patents in these areas. From a therapeutic
approach, the future of pharmacy and pharmacogenomics will be a major guiding tool for drug therapy which will move the
clinical practice away from “one size fits all” approach. Few topics have also been included to cover the research developing
novel diagnostics, biomarkers and preventive solutions using one or more of the core areas of Pharmacogenomics.
The first review article in this special issue contributed by Dr. Andrew Borkowski et al. discusses on the implications of
polymorphisms in warfarin dosing, pharmacogenomics tests available for warfarin dosing along with the clinical model for the
implementation of pharmacogenomics test results and complexities associated with these patented methodologies.
Second review contributed by Dr. John Allen et al. discusses the potential use of pharmacogenomic approaches in the critically
ill for the management of acute coronary syndrome (ACS), invasive fungal infection, and pain management along with
some recent patents associated with it and the current barriers for Pharmacogenomics-guided therapy in the critically ill.
Third review contributed by Dr. Kalyan Chapalamadugu et al. discusses various pharmacogenomics approaches for cardiovascular
complications in patients with metabolic disorders such as diabetes and obesity.
Fourth review contributed by Dr. Ashim Malhotra et al. highlights for the first time on the possible sources of pharmacogenomics
variations that may affect the treatment of the pediatric cardiomyopathy called Barth syndrome (BTHS). In this article
authors also shed light on the possible treatment options along with the future directions.
Fifth article contributed by Dr. Charles Preuss et al. elucidates upon the potential role of nutraceuticals (natural products) as
dietary supplements to prevent or diminish the disease risk in the population carrying certain polymorphisms that can increase
the susceptibility to certain diseases.
Sixth article contributed by Dr. Thea Moore et al. focuses on the current impression of pharmacogenomics in reducing the
life-threatening adverse effects of psychotropics in patients with psychiatric and neurological disorders with special emphasis
on atypical antipsychotics due to their wide usage.
Finally, the seventh article contributed by Dr. Manju Pathak discusses the role of functional foods in disease management
for patients with Type 2 Diabetes Mellitus.
We are grateful to all contributors of this special issue and to all our reviewers for their excellent feedback, which made this
issue a wonderful guide for the future pharmacists and pharmacogenomics specialists. I wish this special issue will give more
encouragement for the scientific community to bring more special issues, topics and books that can promote complete implementation
of pharmacogenomics in clinical settings.